

The role of fibrin(ogen) in wound healing and infection control

Katherine J. Kearney PhD,¹ Robert A.S. Ariëns PhD,^{1,2} Fraser L. Macrae PhD¹

1. Discovery and Translational Science Department; Leeds Institute of Cardiovascular and Metabolic Medicine; University of Leeds; UK

2. Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands.

Corresponding author: Dr. Fraser Macrae

Address: LIGHT Laboratories

University of Leeds

Clarendon Way

Leeds

LS2 9JT

United Kingdom

Email: medfma@leeds.ac.uk

Phone: +44 113 3437734

Word count

Main text: 4704

Abstract: 202

References:210

Table count: 1

Figure count: 3

Running title: Fibrin(ogen) in wound healing and infection control

Manuscript type: Review

Abstract

Fibrinogen, one of the most abundant plasma proteins playing a key role in haemostasis, is an important modulator of wound healing and host defence against microbes. In the current review, we address the role of fibrin(ogen) throughout the process of wound healing and subsequent tissue repair. Initially fibrin(ogen) acts as a provisional matrix supporting incoming leukocytes and acting as reservoir for growth factors. It later goes on to support reepithelialisation, angiogenesis and fibroplasia. Importantly, removal of fibrin(ogen) from the wound is essential for wound healing to progress. We also discuss how fibrin(ogen) functions through a number of mechanisms to protect the host against bacterial infection; by providing a physical barrier, entrapment of bacteria in fibrin(ogen) networks and by directing immune cell function. The central role of fibrin(ogen) in defence against bacterial infection has made it a target of bacterial proteins, evolved to interact with fibrin(ogen) to manipulate clot formation and degradation for the purpose of promoting microbial virulence and survival. Further understanding of the dual roles of fibrin(ogen) in wound healing and infection could provide novel means of therapy to improve recovery from surgical or chronic wounds and help to prevent infection from highly virulent bacterial strains, including those resistant to antibiotics.

INTRODUCTION

Haemostasis begins instantly after injury, with formation of a platelet plug, closely followed by a provisional fibrin matrix. However, the role of the blood clot extends far beyond the cessation of bleeding. Different constituents of the clot help drive the wound healing process forward. Activation of platelets leads to release of vasoactive agents, growth factors and chemokines, while the clot itself concentrates the release of cytokines and growth factors by acting as a reservoir. In addition to its important role of controlling haemorrhage, fibrinogen has the innate capacity to promote wound healing and combat invading bacterial pathogens. As a rapidly formed provisional matrix protein, fibrinogen can serve as a lattice for incoming cells and growth factors, whilst also providing an early line of defence for host protection. Over the decades, significant progress has been made in defining the roles of fibrinogen in both wound healing and host defence.

Fibrinogen is a 340 kDa glycoprotein made up of three pairs of polypeptide chains, A α , B β and γ held together by 29 disulfide bonds.¹ It is the third most abundant of human plasma proteins, after albumin and immunoglobulins, and normally circulates at around 2-4 mg/ml. When clot formation is triggered, thrombin cleaves fibrinopeptides from fibrinogen, thus resulting in conversion of soluble fibrinogen to an insoluble fibrin polymer forming a branching 3D network that is essential for haemostasis (figure 1A-B). The mechanical properties of clots are essential to the functions of fibrin in haemostasis.

FIBRINOGEN IN WOUND HEALING

Once bleeding is controlled, the wound healing process immediately begins with the inflammatory phase. The inflammatory phase is characterised by sequential infiltration of neutrophils, macrophages and lymphocytes attracted by chemokine release and complement activation,^{2,3} and occurs within hours of injury and continues for at least 7 days. Neutrophils and macrophages clean the wound by solubilizing damaged cells and micro-organisms and phagocytosing the debris.^{4,5} Macrophages also release growth factors that stimulate chemotaxis and proliferation of fibroblasts, smooth muscle and endothelial cells and promote angiogenesis.⁶ The proliferative phase occurs between 3-14 days following injury and begins during the inflammatory phase. This phase involves the rebuilding of the wound via reepithelialisation, angiogenesis, granulation tissue formation and collagen deposition. Epithelialisation begins within hours of injury, in an attempt to re-establish a protective barrier between the wound and the environment.⁷ Granulation tissue formation is the final stage in the proliferative phase, where fibroblasts proliferate within the wound site in response to fibronectin and growth factors.⁸ Fibroblasts begin synthesizing collagen, elastin and other extracellular matrix proteins to replace the provisional matrix,^{9,10} and also differentiate into myofibroblasts, allowing for the contraction of the matrix, bringing the wound margins together.¹¹ The final stage in wound healing is tissue remodelling or maturation phase, which begins around day 8 and can continue for up to a year. The main step in this phase is deposition of an organized network of collagen. Abnormalities in this process can lead to compromised wound strength or scar formation.

The orderly formation of the fibrin network following injury and its subsequent removal is essential for uninterrupted progression of wound-healing through these phases (figure 2). Disruption or alterations in fibrin provisional matrix have been shown to have detrimental

effects on the healing process, stalling repair in the inflammatory phase. This has been highlighted in a number of animal models of conditions that effect clot formation, resulting in poor wound healing.¹²

Role of fibrin(ogen) in the provisional extracellular matrix

The fibrin network takes on a new role following haemostasis contributing to the provisional extracellular matrix (ECM). First described in 1982 by Clark et al., fibrin and fibronectin rich matrices were present in biopsies of early stage wound healing, and they stimulated cell migration.¹³ Subsequently, fibrin(ogen) was shown to bind to numerous cells, including neutrophils, monocytes, fibroblasts, and endothelial cells aiding migration, proliferation and organization (figure 2).¹⁴⁻¹⁷ These cells bind directly to fibrin(ogen) by both cell surface integrin receptors¹⁸⁻²¹ and non-integrin receptors (e.g. VE-Cadherin).²² Fibrin matrices can modulate endothelial cell integrin expression, suggesting that a provisional fibrin matrix may be involved in regulation of angiogenesis.²³ However, inadequate removal of the provisional fibrin matrix can lead to healing complications, with plasminogen-deficient mice showing markedly delayed cutaneous wound repair, while crossbreeding these mice with afibrinogenemic mice nullified the delay in wound healing.²⁴

Inflammatory cells

The beginning of the inflammatory phase is determined by the influx of neutrophils and monocytes into the injury site, with neutrophils arriving first due to their larger abundance in circulation. Several factors regulate their influx and activity including chemoattractants,

such as thrombin-cleaved fibrinopeptides from fibrinogen²⁵ and plasmin-derived fibrin degradation products (figure 2).²⁶ Other non-fibrinogen derived elements also attract leukocytes including collagen, elastin, fibronectin, thrombin, complement factors C3a and C5a and transforming growth factor beta (TGF- β).²⁷⁻³²

A leading role of leukocytes is to eliminate contaminating bacteria via phagocytosis, and binding of leukocytes to extracellular matrix proteins, such as fibrin or fibronectin, through integrin receptors ($\alpha_M\beta_2$, $\alpha_v\beta_3$, or Mac-1) modulates this process.³³⁻³⁶ Chemotactic peptides (e.g., C5a) increase integrin receptor Mac-1 expression on neutrophil surfaces,³⁷ and this mediates their adhesion to the Gly-Pro-Arg sequence in the N-terminal domain of the fibrinogen A α -chain.³⁸ Fibrinogen degradation products also induce release of proteases from neutrophils and monocytes,³⁹⁻⁴³ which help to facilitate leukocyte movement across blood vessel basement membranes along with tissue debridement, including degradation of fibrin itself. The ability of fibrin(ogen) to modulate phagocytic and digestive processes suggests it plays an important role in the transition between the inflammatory and tissue repair phases.

Epithelialization

Reepithelialisation is a crucial step in recovering tissue homeostasis and protecting against infection that begins within hours of injury.⁴⁴ Upon damage to the epidermal basement membrane, a provisional matrix containing fibrin and fibronectin forms beneath the epidermis amongst stromal type I collagen bundles at the wound margin.⁴⁵ The epidermis does not migrate over the provisional matrix at the wound surface, but instead epithelial cells from the wound edge and other residual structures quickly migrate through the

provisional matrix, dissecting the clot and desiccated eschar from viable tissue (figure 2).¹³

The migration path appears to be determined by integrins on cell membranes of migrating epidermal cells. In contrast to other epidermal cells, keratinocytes express integrin receptors for fibronectin, tenascin and vitronectin,⁴⁶⁻⁴⁸ but they do not interact with (fibrin)ogen or denatured collagen because they do not express $\alpha V\beta 3$.⁴⁹ This results in the migrating wound epidermis avoiding the fibrin rich clot, migrating down the collagen-rich dermal wound margin and over fibronectin-rich granulation tissue. For dissection of the migrating wound epidermis to occur, breakdown of the extracellular matrix is thought to be facilitated by collagenase and urokinase-type plasminogen activator produced by epidermal cells.⁵⁰⁻⁵² Plasminogen-activators are able to activate collagenase as well as plasminogen bound to fibrin,^{53,54} allowing the degradation of both interstitial collagen and fibrin in the plane of epidermal migration. This is supported by a study that showed delayed wound healing in plasminogen deficient mice following skin injury.²⁴ A lack of fibrin breakdown by plasmin led to a reduction in cellular infiltration (especially keratinocytes) into wound site matrices, but the delay in wound healing was lost in fibrinogen and plasminogen deficient mice. In addition, fibrin can selectively disrupt the adhesion of differentiated keratinocytes preventing cells with less growth potential from migrating into the wound.⁵⁴

Granulation tissue

Approximately three to six days after injury newly forming tissue, known as granulation tissue, begins to form within the wound. Granulation tissue provides a surface for migration of epithelial cells, a barrier to infection, myofibroblasts necessary for wound contraction, and fibroblasts responsible for collagen formation. Macrophages provide growth factors

within the granulation tissue to stimulate fibroplasia and angiogenesis, with fibroblasts helping to form new extracellular matrix to support cell ingrowth, and new blood vessels helping to supply oxygen and nutrients to promote cell metabolism.

Fibroplasia

Fibroplasia is the formation of extracellular matrix by fibroblasts. The migration and proliferation of fibroblasts into the wound begins around 5 days after injury. The clot provides a provisional matrix composed of fibrin, fibronectin and vitronectin,^{13,27,55,56} which alongside growth factors, including platelet-derived growth factor (PDGF)⁵⁷ and TGF- β ,⁵⁸ stimulates fibroblast proliferation and migration from periwound tissue. The constituents of the provisional matrix contribute to tissue formation by providing a scaffold for cell migration and a reservoir of cytokines.^{59,60}

It has been reported that fibronectin mediates fibroblast migration,^{59,61} but fibroblasts can also directly interact with fibrin (figure 2).¹⁶ This likely occurs through Arg-Gly-Asp-Ser (RGDS) sites binding to integrin $\alpha_v\beta_3$, as RGD peptides inhibit the interaction, but other integrins may also play a role such as $\alpha_v\beta_5$ and $\alpha_5\beta_1$.^{21,61,62} Fibrin directly influences fibroblast collagen expression,⁶³ whilst fibrin network structure within the wound appears to impact proliferation and migration.^{64,65} A recent study demonstrated that stiffening of the fibrin network with platelet-like particles promoted fibroblast migration and enhanced wound healing.⁶⁶ The movement of fibroblasts into a fibrin clot may also be facilitated by active proteolytic breakdown of the matrix by fibroblast derived enzymes, including plasminogen activator.^{59,67} Fibrin degradation product, fragment E, is a potent inducer of fibroblast chemotaxis, enhances myofibroblast activation, and is profibrotic in vivo.⁶⁸

Fibroblasts that have migrated into the wound switch to their major function, collagen production.⁹ *In vitro* modelling using fibrin gels has shown that fibroblasts proceed to reorganize the fibrin matrix and subsequently remodel it into collagen-containing tissue (figure 2).⁶⁹

Angiogenesis

Angiogenesis accompanies the fibroplasia process, allowing generation of new blood vessels and delivery of oxygen and nutrients to the new granulation tissue. Angiogenesis is a complex process, relying on both stimulated migration of endothelial cells and appropriate extracellular matrix in the wound bed.⁷⁰ Fibrin is thought to perform two functions in induction and progression of angiogenesis. Firstly, it provides a three-dimensional matrix to support endothelial cell migration and generation of new capillary-like structures.

Fibrinogen has been shown to bind $\alpha_v\beta_3$ -integrin on endothelial cells in humans via RGD-sequence (A α 572–574),^{71,72} and additional non-RGD interactions via binding sites on the γ -chain.⁷³ A porcine full-thickness cutaneous wound model showed that $\alpha_v\beta_3$ plays a fundamental role during invasive angiogenesis in wound healing, demonstrating it is expressed specifically on capillary sprouts invading fibrin clots. Inhibition of $\alpha_v\beta_3$ with cyclic peptides or antibodies inhibited granulation tissue formation.¹⁷ Interestingly though, mice lacking the β_3 -integrin, and therefore the $\alpha_v\beta_3$ complex, have increased angiogenesis in late wound healing,⁷⁴ suggesting that the role of $\alpha_v\beta_3$ in angiogenesis is not clear-cut. Endothelial cells also bind to fibrinogen and fibrin via cell surface integrin receptors $\alpha_v\beta_5$ (via RGD 572-574) and $\alpha_v\beta_1$,⁷⁵⁻⁷⁷ intracellular adhesion molecule-1 (ICAM-1)⁷⁸ and vascular endothelial cadherin (VE-Cadherin).⁷⁹

Secondly, fibrin can act as chemotactic agent to induce endothelial cell migration. Fibrin is essential for sprouting angiogenesis, but purified fibrin matrices alone do not appear enough to induce angiogenesis, and chemotactic agents (vascular endothelial growth factor (VEGF) or basic fibroblast growth factor (bFGF)) are required to stimulate angiogenesis.⁸⁰ Growth factors VEGF, bFGF and PDGF all bind fibrin(ogen),^{60,81,82} and this may be an important property of the fibrin clot in angiogenesis.

Fibrin clot structure has also been suggested to influence new vessel formation. Thinner fibrin fibres have been shown to reduce endothelial cell tubule formation.⁸³ Cross-linking of fibrin α C-regions by FXIIIa increases RGD-dependant interactions of fibrin with endothelial $\alpha_v\beta_3$, $\alpha_v\beta_5$ and $\alpha_5\beta_1$, promoting integrin clustering and increasing cell adhesion and spreading.⁸⁴

Degradation products of fibrin(ogen) may also play a role in angiogenesis progression. While fibrinogen degradation E-fragment has been reported to inhibit both endothelial migration and tubule formation,⁸⁵ its fibrin derived counterpart fibrin E-fragment has been shown to promote proliferation, migration and differentiation of endothelial cells (figure 2).⁸⁶ The inhibitory effects of fibrinogen E-fragment are likely due to a 24-residue stabilized β -bend sequence in fibrinopeptide A, known as alphastatin, that inhibits angiogenesis *in vitro* and *in vivo*.^{87,88}

Fibrinogen deficiency

Some of the strongest evidence for the role of fibrin(ogen) in tissue repair comes from studies that report on wound healing in the absence of fibrinogen. A number of studies have

described impaired wound healing following surgery or slow healing leg ulcers in patients with afibrinogenemia.⁸⁹⁻⁹¹ In support of this, fibrinogen-deficient mice show disorganised patterns of tissue repair including misguided epithelium, delayed wound closure, reduced wound tensile strength and reduced ability to resolve dead space in comparison to wild-type mice.⁹² This suggests that fibrinogen plays a greater role in wound healing than just controlling blood loss, but further studies are needed to explore the role of fibrinogen in other types of injury (e.g., burns, bacterial infection and metabolic disease).

Fibrin sealants

Due to the importance of (fibrin)ogen in the wound healing processes, fibrin sealants are strong candidates as a natural biopolymer scaffolds to improve wound healing. There are several forms of fibrin-glue or fibrin-sealant available, produced from platelet-rich-plasma or from fibrinogen and thrombin mixtures. Fibrin sealants are used widely in surgery to achieve haemostasis, and join or seal tissues rapidly, especially when other wound closure procedures cannot be performed.⁹³ Furthermore, they can be used as conduit to deliver cells, growth factors and drugs to improve wound healing. Use of fibrin as wound healing treatment is a hot topic that has been extensively covered by a number of reviews.⁹⁴⁻⁹⁶ A recent study demonstrated enhanced cell adhesion, migration, and wound healing *in vivo* when neonatal fibrin was used to form fibrin scaffolds in place of adult fibrin.⁹⁷ However, the effects of treatment with fibrin sealants are not always consistent, and variations in the sealant preparations make study comparisons difficult.⁹⁸ Key factors for this include fibrinogen quality and variations in additional factors such as fibronectin, fibrinolysis or coagulation proteins (FXIII, plasminogen, plasminogen activator, plasminogen activator

inhibitor, and thrombin), and growth factors (TGF- β , FGF-2, and VEGF).⁹⁹ Furthermore, a number of clinical studies involve the use of sealants in case series experiments or retrospective analysis without comparative results to appropriate controls. Further studies are required to refine the use of fibrin sealants in wound healing and elucidate the most effective composition to maximise treatment efficacy.

FIBRIN(OGEN) IN BACTERIAL INFECTION

Fibrinogen not only plays a role during haemostasis and wound healing, but also functions in antimicrobial host defence through a number of mechanisms, i.e., by (i) providing a physical barrier at the air-liquid interface, (ii) entrapment of bacteria in fibrinogen or fibrin networks and (iii) supporting the recruitment and activation of host immune cells. On the other hand, the role of host fibrin(ogen) in bacterial infection can be exploited by a number of proteins produced by pathogenic bacteria that target fibrin(ogen) and other components of the host hemostatic system. These bacterial proteins are able to drive fibrin network formation, promote the dissolution of fibrin(ogen) matrices, or simply bind to fibrin(ogen) for the benefit of bacterial survival (figure 3).

Role in host defence

Physical barrier at site of wounds

We reported that fibrin(ogen) forms a structurally distinct “film” at the air-liquid interface, which provides a physical barrier to bacterial movement into a clot.¹⁰⁰ *In vitro* experiments demonstrated that infiltration of *Escherichia coli*, *Staphylococcus epidermidis* and *Staphylococcus aureus* was prevented for at least 12-27 hours by the presence of the fibrin

film. We also established a role for the film *in vivo*, using a murine dermal injury model. Proliferation of *Pseudomonas aeruginosa* was significantly reduced in and around the wound in mice with intact fibrin films. Further work is needed to determine the role of the fibrin film in prevention of systemic infection, by assessing bacterial numbers in blood and organ systems.

Fibrin(ogen) matrices at the site of infection

Formation of fibrin networks at the site of infection can aid the host by entrapping bacteria to limit dissemination, and by supporting the recruitment and activation of host immune cells to aid bacterial clearance.¹⁰¹⁻¹⁰⁵ The protective property of fibrinogen against intracellular bacterium *Listeria monocytogenes* has been demonstrated in a murine peritoneal infection model.¹⁰⁵ Fibrinogen deficient mice had 100% mortality compared to wild-type mice and increased bacterial burden in the liver. Further studies with warfarin distinguished the relative contributions of fibrin vs. fibrinogen in protection against *L. monocytogenes*. Warfarin treatment exacerbated listeriosis, indicating that fibrin was a key determinant to survival that functions by restraining growth of *L. monocytogenes* within infected hepatic tissue, or may restrict cell-to-cell spread of the intracellular bacteria.¹⁰⁵ Entrapment of bacteria by fibrin clot formation also plays a role in preventing the dissemination of *Streptococcus pyogenes*.¹⁰⁶ Mice with genetic deficiency in fibrinogen (Fbg-) were more susceptible to *S. pyogenes* infection than wild-type mice across a range of inoculation doses, and there was increased spread of bacteria to the spleen in Fbg- animals.¹⁰⁶ Further evidence of fibrinogen's protective role was reported in an earlier study, demonstrating that reduction of fibrinogen levels by injection of snake venom ancrod in a murine model of *S. pyogenes* infection enhanced mortality.¹⁰⁷ These data suggest that a

crucial function of fibrinogen in host defence is through formation of fibrin(ogen) barriers (figure 3), limiting bacterial dissemination and supporting local inflammatory clearance mechanisms.¹⁰⁶

Cross-linking of fibrin by FXIIIa further helps to immobilise pathogens within the network, to aid in their containment and clearance by the host immune system.¹⁰⁸ A study by Loof et al. showed that clotting was activated at the bacterial surface via the intrinsic coagulation pathway, and that entrapment of *S. pyogenes* within the fibrin network was FXIII-dependent.¹⁰⁹ Transmission electron microscopy was used to visualise bacterial cells cross-linked to fibrin fibres at multiple sites and further investigation using negative-staining electron microscopy revealed cross-linking of fibrinogen to the bacterial surface via bacterial M1 protein.¹⁰⁹ A murine skin and soft tissue model of *S. pyogenes* M1 infection demonstrated that lack of FXIII leads to increased signs of inflammation and elevated bacterial dissemination.¹¹⁰ FXIII-deficient mice showed impaired survival compared to wild-type mice, with higher bacterial loads detected in blood and spleens compared to wild-type mice or FXIII-deficient mice administered FXIII concentrate.¹¹⁰ These data suggest that there is a protective role for FXIII during early *S. pyogenes* skin infection, by immobilising bacteria within the fibrin clot. Others have shown that FXIIIa also cross-links *S. aureus* and *E. coli* surface proteins to fibrin.¹¹¹

Fibrin(ogen) in immune modulation

Fibrin(ogen) drives cellular activities by serving as a ligand of integrin and non-integrin receptors expressed by inflammatory cells.¹¹²⁻¹¹⁹ These interactions can result in cytokine and chemokine expression, degranulation, phagocytosis, cell adhesion, migration and other effects on leukocyte function.^{113,114,116,120,121} The interaction of leukocyte integrin $\alpha M\beta 2$ with

fibrin(ogen) is well-documented.¹²² α M β 2 is expressed on the surface of key inflammatory cells, including neutrophils, monocytes, macrophages and mast cells, and has a role in development of an inflammatory response *in vivo* by mediating the adhesion of leukocytes to the endothelium, and the subsequent transmigration of adherent cells to the sites of inflammation.^{123,124} Engagement of α M β 2 is mediated by the γ -chain of fibrin,¹²⁵⁻¹²⁷ in a site which is cryptic, and not accessible when fibrinogen is a soluble monomer.¹²⁸ The cryptic nature of the α M β 2 binding motif ensures that leukocyte receptors are not engaged by circulating plasma fibrinogen and instead, α M β 2 is selective for fibrin or for surface-immobilised fibrinogen, such as that found at sites of tissue damage.

The significance of the fibrinogen- α M β 2 interaction was demonstrated in mice expressing a mutant form of fibrinogen lacking the α M β 2 binding motif.¹²⁹ These mutants were less able to eliminate *S. aureus* in a murine acute peritonitis model. Whilst the mutant fibrinogen retained the ability to clot and induce platelet aggregation, it failed to support the α M β 2-mediated adhesion of primary neutrophils and macrophages.¹²⁹ Conversely, in the setting of intravenous infection by *S. aureus*, mice with fibrinogen lacking the α M β 2 binding motif had a survival profile indistinguishable from wild-type mice.¹³⁰ However, fibrinogen deficient mice, and those expressing a mutant fibrinogen lacking the clumping factor A (ClfA) binding motif exhibited a survival advantage over wild-type mice.¹³⁰ Mice with mutant fibrinogen had reduced bacterial burdens in the hearts and kidneys, a dampened pro-inflammatory response, and diminished tissue and organ damage.¹³⁰ These studies demonstrate that while fibrin(ogen) has been repeatedly shown to aid host defence against bacteria, the presence of fibrin(ogen) can also be of use to microbial pathogens during infection.

Fibrinogen can also directly affect an antimicrobial response through release of thrombin cleavage products.¹³¹ A study by Pahlman et al. demonstrated that a fibrinogen cleavage

product, termed GHR28, displayed antimicrobial activity against group A streptococcus (GAS), group B streptococcus (GBS) and *S. aureus*, but not *E. coli* or *Escherichia faecalis*.¹³² Release of fibrinopeptide B from fibrinogen by thrombin exposes a 28 amino acid long peptide sequence at the N-terminal of the β chain, which is subsequently released from fibrinogen by plasmin cleavage, to form GHR28. GHR28 had antimicrobial activity against bacteria that bind fibrinogen to their surface. This peptide caused disruption of the bacterial cell wall and leakage of cytosolic content, signs of bacterial killing.¹³²

Manipulation of fibrin(ogen) by bacterial virulence factors

Modulation of fibrin formation

The local formation of fibrin networks at the site of infection can be detrimental to the host, as incorporation of large numbers of bacteria within fibrinous masses can protect microorganisms from phagocytosis by host immune cells. Inside the clot, bacteria are able to proliferate, leading to the formation of abscesses.^{14,133,134}

S. aureus can directly activate prothrombin through the action of two secreted coagulases, coagulase (Coa) and von Willebrand factor binding protein (vWbp).^{135,136} Coa and vWbp share sequence and structural homology, particularly in their N-terminal regions. These proteins insert N-terminal residues into the activation cleft of zymogen prothrombin, triggering non-proteolytic activation, and formation of staphylothrombin complex.^{137,138} Staphylothrombin is able to convert fibrinogen to fibrin, which covers bacteria with a protective fibrin coat, fibrin-covered bacteria do not activate host immune cells and thus evade phagocytosis (figure 3).¹³⁹ The action of these two coagulases results in formation of two distinct types of fibrin network. Coa activity resulted in formation of a fibrin-containing pseudocapsule closely associated with bacterial microcolonies in an *in vitro* abscess model,

whilst vWbp was responsible for the formation of a fibrinogen/fibrin meshwork situated immediately adjacent to the pseudocapsule.¹⁴⁰ Both types of fibrin network acted as a mechanical barrier against neutrophils.¹⁴⁰ In animal infection models, coagulases are required for full virulence.¹⁴¹⁻¹⁴³ Indeed, Dabigatran (thrombin inhibitor that also inhibits staphylothrombin) has been trialled for use in human patients with *S. aureus* bacteraemia, as an adjunct to antibiotic treatment.¹⁴⁴

Coagulase activity can contribute to bacterial virulence, or to host survival, depending on the location and route of infection. Subcutaneous injection of *S. aureus* lacking Coa significantly reduced proliferation at the infection site, and lessened systemic spread of bacteria.¹⁴⁵ Bacteria lacking Coa were more efficiently cleared by the immune system than wild type bacteria, which showed increased persistence at the site of infection.¹⁴⁵

Conversely, recent work showed that the presence of coagulase protein vWbp in *S. aureus* during peritoneal infection was favourable to host outcome.¹⁴⁶ Mice failed to eliminate *S. aureus* that was deficient in vWbp, however, clearance of these microbes in wild-type mice was restored if active thrombin was added exogenously into the peritoneal cavity.¹⁴⁶ Wild-type mice were able to rapidly and efficiently clear *S. aureus*, whilst Fbg- mice failed to clear the microbe, and this difference in early clearance of bacteria led to all wild-type mice surviving infection even after 2 weeks, while all Fbg- mice died within 24 hours.¹⁴⁶ These studies highlight the importance of fibrin(ogen) in host defence against *S. aureus* in peritoneal infection, and more precisely, the importance of fibrinogen conversion to fibrin. These findings may explain why it is coagulase negative staphylococci that account for the majority of peritoneal infections.¹⁴⁶ An earlier study further supports that fibrin formation is important for protection against *S. aureus* infection in peritoneal infection.¹⁴⁷ In this study, FibAEK mice (with a mutation in the fibrinogen A α -chain, making it insensitive to thrombin

cleavage) showed significantly reduced *S. aureus* clearance from the peritoneal cavity following infection.¹⁴⁷

Clot degradation by bacteria

Many bacteria produce proteins which interact with host fibrinolytic pathways, the best characterised of which are streptokinase, staphylokinase and Pla proteins. Streptokinase is a non-enzymatic plasminogen activator produced by group A, C and G streptococci species.¹⁴⁸

Binding of streptokinase to plasminogen induces a conformational change in the plasminogen activation pocket, non-proteolytically converting it into an active form.¹⁴⁹⁻¹⁵¹

The plasmin-streptokinase complex is protected from inhibition by plasmin specific inhibitor α 2-antiplasmin.¹⁵²

Staphylokinase, produced by *S. aureus* strains is also a non-enzymatic plasminogen activator; however, unlike streptokinase, the staphylokinase-plasmin complex is efficiently inhibited by α 2-antiplasmin.¹⁵³ Staphylokinase activation of plasminogen requires a small amount of plasmin for efficient activation of plasminogen.¹⁵⁴ Staphylokinase binds to plasmin with high affinity, and this staphylokinase-plasmin complex cleaves additional plasminogen to plasmin.¹⁵⁵ It is likely that staphylokinase and streptokinase aid bacterial virulence by preventing entrapment of bacteria by fibrin, allowing for dissemination of bacteria to distant sites in the host (figure 3). In addition to degradation of fibrin matrices, staphylokinase can form complexes with α -defensins secreted from neutrophils, inhibiting their bactericidal effect, further promoting bacterial survival.¹⁵⁶

Unlike these non-enzymatic plasminogen activators, *Y. pestis* express a surface-bound protein, Pla, that has protease activity towards plasminogen.¹⁵⁷ Pla is able to convert plasminogen to plasmin and can also degrade α 2-antiplasmin, which aids bacterial escape

from entrapment in fibrin matrices, and spread through tissue barriers into the circulation.^{158,159}

Other bacteria express plasminogen-binding molecules on their surface, and the bound plasminogen can then be subsequently activated by a number of mechanisms. Streptococcal M and M-like proteins bind plasminogen, which is activated by streptokinase.^{160,161} In addition to expression of staphylokinase, *S. aureus*-produced fibronectin-binding protein B (FnBPB) binds both fibrinogen and plasminogen simultaneously.¹⁶² FnBPB on the surface of *S. aureus* captures plasminogen, which can then be activated by staphylokinase, or by tPA.¹⁶² Whilst streptococci and staphylococci produce their own activators, other bacteria such as *Borrelia burgdorferi*,¹⁶³⁻¹⁶⁵ *Salmonella enteritidis*,¹⁶⁶ and *E. coli*^{166,167} activate bound plasminogen with recruited host tPA or uPA.

In contrast to these plasminogen activating proteins, some strains of *S. pyogenes* secrete a protein with antifibrinolytic action, called protein SIC (streptococcal inhibitor of complement), including strains of the clinically relevant M1 serotype, which are frequently isolated from patients with invasive infections and sepsis.¹⁶⁸ SIC inhibits plasminogen activation by streptokinase, thus enhancing bacterial survival within the clot.¹⁶⁹ A study by Frick et al. demonstrated that SIC⁻ strain is rapidly killed within the clot compared to a SIC expressing strain.¹⁶⁹ Frick et al. speculate that SIC may block the antimicrobial activity of fibrinogen-derived peptides;¹³² by inhibiting plasminogen activation during early infection. Bacteria are able to grow within the clot protected from antimicrobial peptides so that once fibrinolysis is initiated a larger number of bacteria are able to spread to distant sites.¹⁶⁹ Clearly, the manipulation of host fibrin formation and fibrinolysis by bacteria can be beneficial to bacterial survival. Bacteria contain virulence factors that elicit opposing functions, and so a crucial factor in bacterial survival is the timing of the release of such

factors. For example, in *S. aureus*, Coa is produced during the early growth phase¹⁷⁰ while staphylokinase is produced during the late exponential phase.¹⁷¹ It is likely that early release of coagulase allows bacteria to reside and proliferate within protective fibrin clots, before their release following staphylokinase-induced breakdown of the fibrin capsule.¹⁴⁵

Binding to fibrinogen

As described above, bacterial proteins bind and interact with prothrombin and to host fibrinolytic proteins, stimulating fibrin formation and breakdown, respectively. Bacterial virulence factors also directly bind fibrinogen and drive a vast array of functions that benefit bacterial survival (figure 3). The topic of interaction between fibrinogen and bacterial proteins (particularly of *S. aureus*) is well documented and covered by a number of comprehensive reviews.^{139,172-174}

The best characterised of the fibrinogen-binding bacterial virulence factors is ClfA of *S. aureus*. Table 1 summarises ClfA and other fibrinogen-binding bacterial protein function.

CONCLUSIONS

The role of fibrin(ogen) in wound healing and infection control is a story of two sides. Fibrinogen serves multiple roles in promoting wound healing and mediating protection from infection. However, fibrin(ogen) can negatively impact the wound healing process stalling its progression if not removed, whilst bacteria can target the host fibrinogen to promote pathogen virulence. Despite recent advancements in our understanding of fibrinogen's role in wound healing and infection, many unanswered questions remain, some of which have been alluded to throughout this review. An important focus for the future is to try to

understand the role that fibrinogen plays in the interplay between wound healing and bacterial infection. Further determining the molecular and cellular basis of these processes could elucidate novel therapeutic targets to improve recovery from surgical or chronic wounds or help to prevent infection from highly virulent bacterial strains, including those resistant to antibiotics.

ACKNOWLEDGEMENTS

The R.A.S.A. laboratory is supported by grants from the BHF (RG/18/11/34036) and Wellcome Trust (204951/B/16/Z). F.L.M. is supported by a Sir Henry Wellcome Postdoctoral Fellowship (215861/Z/19/Z).

REFERENCES

1. Doolittle RF. Fibrinogen and fibrin. *Annu Rev Biochem.* 1984;53:195-229.
2. Broughton G, 2nd, Janis JE, Attinger CE. The basic science of wound healing. *Plast Reconstr Surg.* 2006;117(7 Suppl):12S-34S.
3. Sinno H, Prakash S. Complements and the wound healing cascade: an updated review. *Plast Surg Int.* 2013;2013:146764.
4. Wilgus TA, Roy S, McDaniel JC. Neutrophils and Wound Repair: Positive Actions and Negative Reactions. *Adv Wound Care (New Rochelle).* 2013;2(7):379-388.
5. Koh TJ, DiPietro LA. Inflammation and wound healing: the role of the macrophage. *Expert Rev Mol Med.* 2011;13:e23.
6. Rappolee D, Werb Z. Macrophage-derived growth factors. In: *Macrophage Biology and Activation.* Springer; 1992:87-140.
7. Rocco M, Weisel JW. Exposed: the elusive alphaC regions in fibrinogen, fibrin protofibrils and fibers. *J Thromb Haemost.* 2015;13(4):567-569.
8. Singer AJ, Clark RA. Cutaneous wound healing. *N Engl J Med.* 1999;341(10):738-746.
9. Welch MP, Odland GF, Clark RA. Temporal relationships of F-actin bundle formation, collagen and fibronectin matrix assembly, and fibronectin receptor expression to wound contraction. *J Cell Biol.* 1990;110(1):133-145.
10. Clark RA, Nielsen LD, Welch MP, McPherson JM. Collagen matrices attenuate the collagen-synthetic response of cultured fibroblasts to TGF-beta. *J Cell Sci.* 1995;108 (Pt 3):1251-1261.
11. Baum J, Duffy HS. Fibroblasts and Myofibroblasts: What Are We Talking About? *J Cardiovasc Pharmacol.* 2011;57(4):376-379.
12. Hoffman M. Animal models of bleeding and tissue repair. *Haemophilia.* 2008;14:62-67.
13. Clark RA, Lanigan JM, DellaPelle P, Manseau E, Dvorak HF, Colvin RB. Fibronectin and fibrin provide a provisional matrix for epidermal cell migration during wound reepithelialization. *J Invest Dermatol.* 1982;79(5):264-269.
14. Ciano PS, Colvin RB, Dvorak AM, McDonagh J, Dvorak HF. Macrophage migration in fibrin gel matrices. *Lab Invest.* 1986;54(1):62-70.
15. Lanir N, Ciano PS, Van de Water L, McDonagh J, Dvorak AM, Dvorak HF. Macrophage migration in fibrin gel matrices. II. Effects of clotting factor XIII, fibronectin, and glycosaminoglycan content on cell migration. *J Immunol.* 1988;140(7):2340-2349.
16. Brown LF, Lanir N, McDonagh J, Tognazzi K, Dvorak AM, Dvorak HF. Fibroblast migration in fibrin gel matrices. *Am J Pathol.* 1993;142(1):273-283.
17. Clark RA, Tonnesen MG, Gailit J, Cheresch DA. Transient functional expression of alphaVbeta 3 on vascular cells during wound repair. *Am J Pathol.* 1996;148(5):1407-1421.
18. Hynes RO. Integrins - Versatility, Modulation, and Signaling in Cell-Adhesion. *Cell.* 1992;69(1):11-25.
19. Cheresch DA, Berliner SA, Vicente V, Ruggeri ZM. Recognition of Distinct Adhesive Sites on Fibrinogen by Related Integrins on Platelets and Endothelial-Cells. *Cell.* 1989;58(5):945-953.
20. Newman D, Clark RAF, Mosesson MW, Tonnesen MG. Human dermal microvascular endothelial cells use alpha 5 beta 1, as well as alpha v beta 3, to interact with the major fibrinogen breakdown product E1. *J Invest Dermatol.* 1996;106(4):105-105.
21. Gailit J, Clarke C, Newman D, Tonnesen MG, Mosesson MW, Clark RAF. Human fibroblasts bind directly to fibrinogen at RGD sites through integrin alpha v beta 3. *Exp Cell Res.* 1997;232(1):118-126.
22. Martinez J, Ferber A, Bach TL, Yaen CH. Interaction of fibrin with VE-cadherin. *Fibrinogen.* 2001;936:386-405.
23. Feng XD, Clark RAF, Galanakis D, Tonnesen MG. Fibrin and collagen differentially regulate human dermal microvascular endothelial cell integrins: Stabilization of alpha v/beta 3 mRNA by fibrin. *J Invest Dermatol.* 1999;113(6):913-919.

24. Bugge TH, Kombrinck KW, Flick MJ, Daugherty CC, Danton MJ, Degen JL. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. *Cell*. 1996;87(4):709-719.
25. Richardson DL, Pepper DS, Kay AB. Chemotaxis for Human Monocytes by Fibrinogen-Derived Peptides. *Brit J Haematol*. 1976;32(4):507-513.
26. Gross TJ, Leavell KJ, Peterson MW. CD11b/CD18 mediates the neutrophil chemotactic activity of fibrin degradation product D domain. *Thromb Haemost*. 1997;77(5):894-900.
27. Postlethwaite AE, Kang AH. Collagen-Induced and Collagen Peptide-Induced Chemotaxis of Human-Blood Monocytes. *J Exp Med*. 1976;143(6):1299-1307.
28. Senior RM, Griffin GL, Mecham RP. Chemotactic Activity of Elastin-Derived Peptides. *J Clin Invest*. 1980;66(4):859-862.
29. Clark RAF, Wikner NE, Doherty DE, Norris DA. Cryptic Chemotactic Activity of Fibronectin for Human-Monocytes Resides in the 120-Kda Fibroblastic Cell-Binding Fragment. *J Biol Chem*. 1988;263(24):12115-12123.
30. Barshavit R, Benezra M, Eldor A, et al. Thrombin Immobilized to Extracellular-Matrix Is a Potent Mitogen for Vascular Smooth-Muscle Cells - Nonenzymatic Mode of Action. *Cell Regul*. 1990;1(6):453-463.
31. Fernandez HN, Henson PM, Otani A, Hugli TE. Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions. *J Immunol*. 1978;120(1):109-115.
32. Wahl SM, Hunt DA, Wakefield LM, et al. Transforming Growth-Factor Type-Beta Induces Monocyte Chemotaxis and Growth-Factor Production. *Proc Natl Acad Sci U S A*. 1987;84(16):5788-5792.
33. Blystone SD, Graham IL, Lindberg FP, Brown EJ. Integrin Alpha(V)Beta(3) Differentially Regulates Adhesive and Phagocytic Functions of the Fibronectin Receptor Alpha(5)Beta(1). *J Cell Bio*. 1994;127(4):1129-1137.
34. Altieri DC, Agbanyo FR, Plescia J, Ginsberg MH, Edgington TS, Plow EF. A Unique Recognition Site Mediates the Interaction of Fibrinogen with the Leukocyte Integrin Mac-1 (Cd11b Cd18). *J Biol Chem*. 1990;265(21):12119-12122.
35. Trezzini C, Schuepp B, Maly FE, Jungi TW. Evidence That Exposure to Fibrinogen or to Antibodies Directed against Mac-1 (Cd11b/Cd18-Cr3) Modulates Human Monocyte Effector Functions. *Brit J Haematol*. 1991;77(1):16-24.
36. Yakovlev S, Li Z, Ugarova T, Medved L. Interaction of fibrin(ogen) with leukocyte receptor alpha(M)beta(2) (Mac-1): Further characterization and identification of a novel binding region within the central domain of the fibrinogen gamma-module. *Biochemistry*. 2005;44(2):617-626.
37. Tonnesen MG, Anderson DC, Springer TA, Knedler A, Avdi N, Henson PM. Adherence of Neutrophils to Cultured Human Microvascular Endothelial-Cells - Stimulation by Chemotactic Peptides and Lipid Mediators and Dependence Upon the Mac-1, Lfa-1, P150,95 Glycoprotein Family. *J Clin Invest*. 1989;83(2):637-646.
38. Loike JD, Sodeik B, Cao L, et al. Cd11c/Cd18 on Neutrophils Recognizes a Domain at the N Terminus of the a-Alpha Chain of Fibrinogen. *Proc Natl Acad Sci U S A*. 1991;88(3):1044-1048.
39. Wojtecka-Lukasik E, Maslinski S. Fibronectin and fibrinogen degradation products stimulate PMN-leukocyte and mast cell degranulation. *J Physiol Pharmacol*. 1992;43(2):173-181.
40. Plow EF. The contribution of leukocyte proteases to fibrinolysis. *Blut*. 1986;53(1):1-9.
41. Machovich R, Himer A, Owen WG. Neutrophil proteases in plasminogen activation. *Blood Coagul Fibrinolysis*. 1990;1(3):273-277.
42. Adams SA, Kelly SL, Kirsch RE, Robson SC, Shephard EG. Role of neutrophil membrane proteases in fibrin degradation. *Blood Coagul Fibrinolysis*. 1995;6(8):693-702.

43. Hamaguchi M, Morishita Y, Takahashi I, Ogura M, Takamatsu J, Saito H. Fdp D-Dimer Induces the Secretion of Interleukin-1, Urokinase-Type Plasminogen-Activator, and Plasminogen-Activator Inhibitor-2 in a Human Promonocytic Leukemia-Cell Line. *Blood*. 1991;77(1):94-100.
44. Pastar I, Stojadinovic O, Yin NC, et al. Epithelialization in Wound Healing: A Comprehensive Review. *Adv Wound Care (New Rochelle)*. 2014;3(7):445-464.
45. Odland G, Ross R. Human Wound Repair .1. Epidermal Regeneration. *J Cell Biol*. 1968;39(1):135-+.
46. Clark RAF. Fibronectin Matrix Deposition and Fibronectin Receptor Expression in Healing and Normal Skin. *J Invest Dermatol*. 1990;94(6):S128-S134.
47. Larjava H, Salo T, Haapasalmi K, Kramer RH, Heino J. Expression of Integrins and Basement-Membrane Components by Wound Keratinocytes. *J Clin Invest*. 1993;92(3):1425-1435.
48. Juhasz I, Murphy GF, Yan HC, Herlyn M, Albelda SM. Regulation of Extracellular-Matrix Proteins and Integrin Cell-Substratum Adhesion Receptors on Epithelium during Cutaneous Human Wound-Healing in-Vivo. *Am J Pathol*. 1993;143(5):1458-1469.
49. Kubo M, Van De Water L, Plantefaber LC, et al. Fibrinogen and fibrin are anti-adhesive for keratinocytes: A mechanism for fibrin eschar slough during wound repair. *J Invest Dermatol*. 2001;117(6):1369-1381.
50. Pilcher BK, Dumin JA, Sudbeck BD, Krane SM, Welgus HG, Parks WC. The activity of collagenase-1 is required for keratinocyte migration on a type I collagen matrix. *J Cell Biol*. 1997;137(6):1445-1457.
51. Grøndahl-Hansen J, Lund LR, Ralfkiær E, Ottevanger V, Danø K. Urokinase- and Tissue-Type Plasminogen Activators in Keratinocytes During Wound Reepithelialization In Vivo. *J Invest Dermatol*. 1988;90(6):790-795.
52. Woodley DT, Kalebec T, Banes AJ, Link W, Prunieras M, Liotta L. Adult Human Keratinocytes Migrating over Nonviable Dermal Collagen Produce Collagenolytic Enzymes That Degrade Type-I and Type-Iv Collagen. *J Invest Dermatol*. 1986;86(4):418-423.
53. Mignatti P, Rifkin DB, Welgus HG, Parks WC. Proteinases and Tissue Remodeling. In: Clark RAF, ed. *The Molecular and Cellular Biology of Wound Repair*. Boston, MA: Springer US; 1988:427-474.
54. Geer DJ, Andreadis ST. A novel role of fibrin in epidermal healing: plasminogen-mediated migration and selective detachment of differentiated keratinocytes. *J Invest Dermatol*. 2003;121(5):1210-1216.
55. Gray AJ, Bishop JE, Reeves JT, Laurent GJ. A alpha and B beta chains of fibrinogen stimulate proliferation of human fibroblasts. *J Cell Sci*. 1993;104 (Pt 2):409-413.
56. Xu J, Clark RA. Extracellular matrix alters PDGF regulation of fibroblast integrins. *J Cell Biol*. 1996;132(1-2):239-249.
57. Lynch SE, Nixon JC, Colvin RB, Antoniades HN. Role of Platelet-Derived Growth-Factor in Wound-Healing - Synergistic Effects with Other Growth-Factors. *Proc Natl Acad Sci U S A*. 1987;84(21):7696-7700.
58. Faler BJ, Macsata RA, Plummer D, Mishra L, Sidawy AN. Transforming growth factor-beta and wound healing. *Perspect Vasc Surg Endovasc Ther*. 2006;18(1):55-62.
59. Greiling D, Clark RA. Fibronectin provides a conduit for fibroblast transmigration from collagenous stroma into fibrin clot provisional matrix. *J Cell Sci*. 1997;110 (Pt 7):861-870.
60. Sahni A, Odrliin T, Francis CW. Binding of basic fibroblast growth factor to fibrinogen and fibrin. *J Biol Chem*. 1998;273(13):7554-7559.
61. Gailit J, Clark RA. Studies in vitro on the role of alpha v and beta 1 integrins in the adhesion of human dermal fibroblasts to provisional matrix proteins fibronectin, vitronectin, and fibrinogen. *J Invest Dermatol*. 1996;106(1):102-108.
62. Farrell DH, AlMondhiry HA. Human fibroblast adhesion to fibrinogen. *Thromb Haemost*. 1997:P1392-P1392.

63. Law JX, Chowdhury SR, Aminuddin BS, Ruszymah BHI. Role of plasma-derived fibrin on keratinocyte and fibroblast wound healing. *Cell Tissue Bank*. 2017;18(4):585-595.
64. Sporn LA, Bunce LA, Francis CW. Cell proliferation on fibrin: modulation by fibrinopeptide cleavage. *Blood*. 1995;86(5):1802-1810.
65. Cox S, Cole M, Tawil B. Behavior of human dermal fibroblasts in three-dimensional fibrin clots: Dependence on fibrinogen and thrombin concentration. *Tissue Eng*. 2004;10(5-6):942-954.
66. Nandi S, Sproul EP, Nellenbach K, et al. Platelet-like particles dynamically stiffen fibrin matrices and improve wound healing outcomes. *Biomater Sci*. 2019;7(2):669-682.
67. Knox P, Crooks S, Scaife MC, Patel S. Role of Plasminogen, Plasmin, and Plasminogen Activators in the Migration of Fibroblasts into Plasma Clots. *J Cell Physiol*. 1987;132(3):501-508.
68. Fuchs PO, Calitz C, Pavlovic N, et al. Fibrin fragment E potentiates TGF-beta-induced myofibroblast activation and recruitment. *Cell Signal*. 2020;72:109661.
69. Tuan TL, Song A, Chang S, Younai S, Nimni ME. In vitro fibroplasia: Matrix contraction, cell growth, and collagen production of fibroblasts cultured in fibrin gels. *Exp Cell Res*. 1996;223(1):127-134.
70. Madri JA, Sankar S, Romanic AM. Angiogenesis. In: Clark RAF, ed. *The Molecular and Cellular Biology of Wound Repair*. Plenum Press, New York; 1996:355-372.
71. Thiagarajan P, Rippon AJ, Farrell DH. Alternative adhesion sites in human fibrinogen for vascular endothelial cells. *Biochemistry*. 1996;35(13):4169-4175.
72. Sahni A, Francis CW. Stimulation of endothelial cell proliferation by FGF-2 in the presence of fibrinogen requires alphavbeta3. *Blood*. 2004;104(12):3635-3641.
73. Yokoyama K, Zhang XP, Medved L, Takada Y. Specific binding of integrin alpha v beta 3 to the fibrinogen gamma and alpha(E) chain C-terminal domains. *Biochemistry*. 1999;38(18):5872-5877.
74. Reynolds LE, Conti FJ, Lucas M, et al. Accelerated re-epithelialization in beta(3)-integrin-deficient mice is associated with enhanced TGF-beta 1 signaling. *Nat Med*. 2005;11(2):167-174.
75. Rybarczyk BJ, Lawrence SO, Simpson-Haidaris PJ. Matrix-fibrinogen enhances wound closure by increasing both cell proliferation and migration. *Blood*. 2003;102(12):4035-4043.
76. Nisato RE, Tille JC, Jonczyk A, Goodman SL, Pepper MS. alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. *Angiogenesis*. 2003;6(2):105-119.
77. Suehiro K, Gailit J, Plow EF. Fibrinogen is a ligand for integrin alpha(5)beta(1) on endothelial cells. *J Biol Chem*. 1997;272(8):5360-5366.
78. Altieri DC, Duperray A, Plescia J, Thornton GB, Languino LR. Structural Recognition of a Novel Fibrinogen Gamma-Chain Sequence(117-133) by Intercellular-Adhesion Molecule-1 Mediates Leukocyte-Endothelium Interaction. *J Biol Chem*. 1995;270(2):696-699.
79. Bach TL, Barsigian C, Chalupowicz DG, et al. VE-cadherin mediates endothelial cell capillary tube formation in fibrin and collagen gels. *Exp Cell Res*. 1998;238(2):324-334.
80. Feng X, Tonnesen MG, Mousa SA, Clark RA. Fibrin and collagen differentially but synergistically regulate sprout angiogenesis of human dermal microvascular endothelial cells in 3-dimensional matrix. *Int J Cell Biol*. 2013;2013:231279.
81. Sahni A, Francis CW. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. *Blood*. 2000;96(12):3772-3778.
82. Martino MM, Briquez PS, Ranga A, Lutolf MP, Hubbell JA. Heparin-binding domain of fibrin(ogen) binds growth factors and promotes tissue repair when incorporated within a synthetic matrix. *Proc Natl Acad Sci U S A*. 2013;110(12):4563-4568.
83. Nehls V, Herrmann R. The configuration of fibrin clots determines capillary morphogenesis and endothelial cell migration. *Microvasc Res*. 1996;51(3):347-364.

84. Belkin AM, Tsurupa G, Zemskov E, Veklich Y, Weisel JW, Medved L. Transglutaminase-mediated oligomerization of the fibrin(ogen) alpha C domains promotes integrin-dependent cell adhesion and signaling. *Blood*. 2005;105(9):3561-3568.
85. Bootle-Wilbraham CA, Tazzyman S, Marshall JM, Lewis CE. Fibrinogen E-fragment inhibits the migration and tubule formation of human dermal microvascular endothelial cells in vitro. *Cancer Res*. 2000;60(17):4719-4724.
86. Bootle-Wilbraham CA, Tazzyman S, Thompson WD, Stirk CM, Lewis CE. Fibrin fragment E stimulates the proliferation, migration and differentiation of human microvascular endothelial cells in vitro. *Angiogenesis*. 2001;4(4):269-275.
87. Brown NJ, Staton CA, Rodgers GR, Corke KP, Underwood JC, Lewis CE. Fibrinogen E fragment selectively disrupts the vasculature and inhibits the growth of tumours in a syngeneic murine model. *Br J Cancer*. 2002;86(11):1813-1816.
88. Staton CA, Brown NJ, Rodgers GR, et al. Alphastatin, a 24-amino acid fragment of human fibrinogen, is a potent new inhibitor of activated endothelial cells in vitro and in vivo. *Blood*. 2004;103(2):601-606.
89. Kinebuchi A, Ohtsuka T, Ishida S, et al. Leg ulcer presenting in a patient with congenital afibrinogenemia. *Eur J Dermatol*. 2002;12(1):70-72.
90. Lak M, Keihani M, Elahi F, Peyvandi F, Mannucci PM. Bleeding and thrombosis in 55 patients with inherited afibrinogenemia. *Br J Haematol*. 1999;107(1):204-206.
91. Rupec RA, Kind P, Ruzicka T. Cutaneous manifestations of congenital afibrinogenemia. *Br J Dermatol*. 1996;134(3):548-550.
92. Drew AF, Liu H, Davidson JM, Daugherty CC, Degen JL. Wound-healing defects in mice lacking fibrinogen. *Blood*. 2001;97(12):3691-3698.
93. Rosso F, Marino G, Giordano A, Barbarisi M, Parmeggiani D, Barbarisi A. Smart materials as scaffolds for tissue engineering. *J Cell Physiol*. 2005;203(3):465-470.
94. Whelan D, Caplice NM, Clover AJ. Fibrin as a delivery system in wound healing tissue engineering applications. *J Control Release*. 2014;196:1-8.
95. Miron RJ, Fujioka-Kobayashi M, Bishara M, Zhang Y, Hernandez M, Choukroun J. Platelet-Rich Fibrin and Soft Tissue Wound Healing: A Systematic Review. *Tissue Eng Part B Rev*. 2017;23(1):83-99.
96. Heher P, Muhleder S, Mittermayr R, Redl H, Slezak P. Fibrin-based delivery strategies for acute and chronic wound healing. *Adv Drug Deliv Rev*. 2018;129:134-147.
97. Nellenbach K, Nandi S, Peeler C, Kyu A, Brown AC. Neonatal Fibrin Scaffolds Promote Enhanced Cell Adhesion, Migration, and Wound Healing In Vivo Compared to Adult Fibrin Scaffolds. *Cell Mol Bioeng*. 2020;13(5):393-404.
98. de Carvalho CKL, Fernandes BL, de Souza MA. Autologous Matrix of Platelet-Rich Fibrin in Wound Care Settings: A Systematic Review of Randomized Clinical Trials. *J Funct Biomater*. 2020;11(2).
99. Clark RA. Fibrin glue for wound repair: facts and fancy. *Thromb Haemost*. 2003;90(6):1003-1006.
100. Macrae FL, Duval C, Papareddy P, et al. A fibrin biofilm covers blood clots and protects from microbial invasion. *J Clin Invest*. 2018;128(8):3356-3368.
101. Dunn DL, Simmons RL. Fibrin in peritonitis. III. The mechanism of bacterial trapping by polymerizing fibrin. *Surgery*. 1982;92(3):513-519.
102. Kapral FA. Clumping of *Staphylococcus aureus* in the peritoneal cavity of mice. *J Bacteriol*. 1966;92(4):1188-1195.
103. Echtenacher B, Weigl K, Lehn N, Mannel DN. Tumor necrosis factor-dependent adhesions as a major protective mechanism early in septic peritonitis in mice. *Infect Immun*. 2001;69(6):3550-3555.
104. Rotstein OD. Role of fibrin deposition in the pathogenesis of intraabdominal infection. *Eur J Clin Microbiol Infect Dis*. 1992;11(11):1064-1068.

105. Mullarky IK, Szaba FM, Berggren KN, et al. Infection-stimulated fibrin deposition controls hemorrhage and limits hepatic bacterial growth during listeriosis. *Infect Immun*. 2005;73(7):3888-3895.
106. Sun H, Wang X, Degen JL, Ginsburg D. Reduced thrombin generation increases host susceptibility to group A streptococcal infection. *Blood*. 2009;113(6):1358-1364.
107. Sun HM, Ringdahl U, Homeister JW, et al. Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. *Science*. 2004;305(5688):1283-1286.
108. Dickneite G, Herwald H, Korte W, Allanore Y, Denton CP, Matucci Cerinic M. Coagulation factor XIII: a multifunctional transglutaminase with clinical potential in a range of conditions. *Thromb Haemost*. 2015;113(4):686-697.
109. Loof TG, Morgelin M, Johansson L, et al. Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense. *Blood*. 2011;118(9):2589-2598.
110. Deicke C, Chakrakodi B, Pils MC, et al. Local activation of coagulation factor XIII reduces systemic complications and improves the survival of mice after *Streptococcus pyogenes* M1 skin infection. *Int J Med Microbiol*. 2016;306(7):572-579.
111. Wang Z, Wilhelmsson C, Hyrsi P, et al. Pathogen entrapment by transglutaminase--a conserved early innate immune mechanism. *Plos Pathogens*. 2010;6(2):e1000763.
112. Duperray A, Languino LR, Plescia J, et al. Molecular identification of a novel fibrinogen binding site on the first domain of ICAM-1 regulating leukocyte-endothelium bridging. *J Biol Chem*. 1997;272(1):435-441.
113. Sitrin RG, Pan PM, Srikanth S, Todd RF, 3rd. Fibrinogen activates NF-kappa B transcription factors in mononuclear phagocytes. *J Immunol*. 1998;161(3):1462-1470.
114. Rubel C, Fernandez GC, Dran G, Bompadre MB, Isturiz MA, Palermo MS. Fibrinogen promotes neutrophil activation and delays apoptosis. *J Immunol*. 2001;166(3):2002-2010.
115. Forsyth CB, Solovjov DA, Ugarova TP, Plow EF. Integrin alpha(M)beta(2)-mediated cell migration to fibrinogen and its recognition peptides. *J Exp Med*. 2001;193(10):1123-1133.
116. Tuluc F, Garcia A, Bredetean O, Meshki J, Kunapuli SP. Primary granule release from human neutrophils is potentiated by soluble fibrinogen through a mechanism depending on multiple intracellular signaling pathways. *Am J Physiol Cell Physiol*. 2004;287(5):C1264-1272.
117. Pillay J, Kamp VM, Pennings M, et al. Acute-phase concentrations of soluble fibrinogen inhibit neutrophil adhesion under flow conditions in vitro through interactions with ICAM-1 and MAC-1 (CD11b/CD18). *J Thromb Haemost*. 2013;11(6):1172-1182.
118. Yakovlev S, Gao Y, Cao C, et al. Interaction of fibrin with VE-cadherin and anti-inflammatory effect of fibrin-derived fragments. *J Thromb Haemost*. 2011;9(9):1847-1855.
119. Antoniak S. The coagulation system in host defense. *Res Pract Thromb Haemost*. 2018;2(3):549-557.
120. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. *J Immunol*. 2001;167(5):2887-2894.
121. Rubel C, Gomez S, Fernandez GC, Isturiz MA, Caamano J, Palermo MS. Fibrinogen-CD11b/CD18 interaction activates the NF-kappa B pathway and delays apoptosis in human neutrophils. *Eur J Immunol*. 2003;33(5):1429-1438.
122. Luyendyk JP, Schoenecker JG, Flick MJ. The multifaceted role of fibrinogen in tissue injury and inflammation. *Blood*. 2019;133(6):511-520.
123. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. *Cell*. 1994;76(2):301-314.
124. Flick MJ, Du X, Degen JL. Fibrin(ogen)-alpha M beta 2 interactions regulate leukocyte function and innate immunity in vivo. *Exp Biol Med (Maywood)*. 2004;229(11):1105-1110.
125. Ugarova TP, Solovjov DA, Zhang L, et al. Identification of a novel recognition sequence for integrin alphaM beta2 within the gamma-chain of fibrinogen. *J Biol Chem*. 1998;273(35):22519-22527.

126. Yakubenko VP, Solovjov DA, Zhang L, Yee VC, Plow EF, Ugarova TP. Identification of the binding site for fibrinogen recognition peptide gamma 383-395 within the alpha(M)I-domain of integrin alpha(M)beta2. *J Biol Chem*. 2001;276(17):13995-14003.
127. Ugarova TP, Lishko VK, Podolnikova NP, et al. Sequence gamma 377-395(P2), but not gamma 190-202(P1), is the binding site for the alpha MI-domain of integrin alpha M beta 2 in the gamma C-domain of fibrinogen. *Biochemistry*. 2003;42(31):9365-9373.
128. Lishko VK, Kudryk B, Yakubenko VP, Yee VC, Ugarova TP. Regulated unmasking of the cryptic binding site for integrin alpha M beta 2 in the gamma C-domain of fibrinogen. *Biochemistry*. 2002;41(43):12942-12951.
129. Flick MJ, Du X, Witte DP, et al. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. *J Clin Invest*. 2004;113(11):1596-1606.
130. Flick MJ, Du X, Prasad JM, et al. Genetic elimination of the binding motif on fibrinogen for the *S. aureus* virulence factor ClfA improves host survival in septicemia. *Blood*. 2013;121(10):1783-1794.
131. Tang YQ, Yeaman MR, Selsted ME. Antimicrobial peptides from human platelets. *Infect Immun*. 2002;70(12):6524-6533.
132. Pahlman LI, Morgelin M, Kasetty G, Olin AI, Schmidtchen A, Herwald H. Antimicrobial activity of fibrinogen and fibrinogen-derived peptides--a novel link between coagulation and innate immunity. *Thromb Haemost*. 2013;109(5):930-939.
133. Hudspeth AS. Radical surgical debridement in the treatment of advanced generalized bacterial peritonitis. *Arch Surg*. 1975;110(10):1233-1236.
134. Ahrenholz DH, Simmons RL. Fibrin in peritonitis. I. Beneficial and adverse effects of fibrin in experimental *E. coli* peritonitis. *Surgery*. 1980;88(1):41-47.
135. Bjerketorp J, Jacobsson K, Frykberg L. The von Willebrand factor-binding protein (vWbp) of *Staphylococcus aureus* is a coagulase. *FEMS Microbiol Lett*. 2004;234(2):309-314.
136. Kawabata S, Morita T, Iwanaga S, Igarashi H. Enzymatic properties of staphylothrombin, an active molecular complex formed between staphylocoagulase and human prothrombin. *J Biochem*. 1985;98(6):1603-1614.
137. Friedrich R, Panizzi P, Fuentes-Prior P, et al. Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation. *Nature*. 2003;425(6957):535-539.
138. Kroh HK, Panizzi P, Bock PE. Von Willebrand factor-binding protein is a hysteretic conformational activator of prothrombin. *Proc Natl Acad Sci U S A*. 2009;106(19):7786-7791.
139. Crosby HA, Kwiecinski J, Horswill AR. *Staphylococcus aureus* Aggregation and Coagulation Mechanisms, and Their Function in Host-Pathogen Interactions. *Adv Appl Microbiol*. 2016;96:1-41.
140. Guggenberger C, Wolz C, Morrissey JA, Heesemann J. Two distinct coagulase-dependent barriers protect *Staphylococcus aureus* from neutrophils in a three dimensional in vitro infection model. *Plos Pathog*. 2012;8(1):e1002434.
141. Cheng AG, McAdow M, Kim HK, Bae T, Missiakas DM, Schneewind O. Contribution of Coagulases towards *Staphylococcus aureus* Disease and Protective Immunity. *Plos Pathog*. 2010;6(8).
142. Vanassche T, Verhaegen J, Peetermans WE, et al. Inhibition of staphylothrombin by dabigatran reduces *Staphylococcus aureus* virulence. *J Thromb Haemost*. 2011;9(12):2436-2446.
143. Panizzi P, Nahrendorf M, Figueiredo JL, et al. In vivo detection of *Staphylococcus aureus* endocarditis by targeting pathogen-specific prothrombin activation. *Nat Med*. 2011;17(9):1142-1146.
144. Peetermans M, Liesenborghs L, Peerlinck K, et al. Targeting Coagulase Activity in *Staphylococcus aureus* Bacteraemia: A Randomized Controlled Single-Centre Trial of Staphylothrombin Inhibition. *Thromb Haemost*. 2018;118(5):818-829.

145. Loof TG, Goldmann O, Naudin C, et al. Staphylococcus aureus-induced clotting of plasma is an immune evasion mechanism for persistence within the fibrin network. *Microbiology (Reading)*. 2015;161(Pt 3):621-627.
146. Prasad JM, Negron O, Du X, et al. Host fibrinogen drives antimicrobial function in Staphylococcus aureus peritonitis through bacterial-mediated prothrombin activation. *Proc Natl Acad Sci U S A*. 2021;118(1).
147. Prasad JM, Gorkun OV, Raghu H, et al. Mice expressing a mutant form of fibrinogen that cannot support fibrin formation exhibit compromised antimicrobial host defense. *Blood*. 2015;126(17):2047-2058.
148. van der Poll T, Herwald H. The coagulation system and its function in early immune defense. *Thromb Haemost*. 2014;112(4):640-648.
149. Wang X, Lin X, Loy JA, Tang J, Zhang XC. Crystal structure of the catalytic domain of human plasmin complexed with streptokinase. *Science*. 1998;281(5383):1662-1665.
150. Boxrud PD, Fay WP, Bock PE. Streptokinase binds to human plasmin with high affinity, perturbs the plasmin active site, and induces expression of a substrate recognition exosite for plasminogen. *J Biol Chem*. 2000;275(19):14579-14589.
151. Panizzi P, Boxrud PD, Verhamme IM, Bock PE. Binding of the COOH-terminal lysine residue of streptokinase to plasmin(ogen) kringles enhances formation of the streptokinase.plasmin(ogen) catalytic complexes. *J Biol Chem*. 2006;281(37):26774-26778.
152. Wiman B. On the reaction of plasmin or plasmin-streptokinase complex with aprotinin or alpha 2-antiplasmin. *Thromb Res*. 1980;17(1-2):143-152.
153. Lijnen HR, Van Hoef B, De Cock F, et al. On the mechanism of fibrin-specific plasminogen activation by staphylokinase. *J Biol Chem*. 1991;266(18):11826-11832.
154. Grella DK, Castellino FJ. Activation of human plasminogen by staphylokinase. Direct evidence that preformed plasmin is necessary for activation to occur. *Blood*. 1997;89(5):1585-1589.
155. Collen D, Schlott B, Engelborghs Y, et al. On the mechanism of the activation of human plasminogen by recombinant staphylokinase. *J Biol Chem*. 1993;268(11):8284-8289.
156. Jin T, Bokarewa M, Foster T, Mitchell J, Higgins J, Tarkowski A. Staphylococcus aureus resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. *J Immunol*. 2004;172(2):1169-1176.
157. Sodeinde OA, Subrahmanyam YVBK, Stark K, Quan T, Bao YD, Goguen JD. A Surface Protease and the Invasive Character of Plague. *Science*. 1992;258(5084):1004-1007.
158. Kukkonen M, Lahteenmaki K, Suomalainen M, et al. Protein regions important for plasminogen activation and inactivation of alpha2-antiplasmin in the surface protease Pla of Yersinia pestis. *Mol Microbiol*. 2001;40(5):1097-1111.
159. Lathem WW, Price PA, Miller VL, Goldman WE. A plasminogen-activating protease specifically controls the development of primary pneumonic plague. *Science*. 2007;315(5811):509-513.
160. Berge A, Sjobring U. PAM, a novel plasminogen-binding protein from Streptococcus pyogenes. *J Biol Chem*. 1993;268(34):25417-25424.
161. Ben Nasr A, Wistedt A, Ringdahl U, Sjobring U. Streptokinase activates plasminogen bound to human group C and G streptococci through M-like proteins. *Eur J Biochem*. 1994;222(2):267-276.
162. Pietrocola G, Nobile G, Gianotti V, et al. Molecular Interactions of Human Plasminogen with Fibronectin-binding Protein B (FnBPB), a Fibrinogen/Fibronectin-binding Protein from Staphylococcus aureus. *J Biol Chem*. 2016;291(35):18148-18162.
163. Klempner MS, Noring R, Epstein MP, et al. Binding of human plasminogen and urokinase-type plasminogen activator to the Lyme disease spirochete, Borrelia burgdorferi. *J Infect Dis*. 1995;171(5):1258-1265.

164. Fuchs H, Wallich R, Simon MM, Kramer MD. The outer surface protein A of the spirochete *Borrelia burgdorferi* is a plasmin(ogen) receptor. *Proc Natl Acad Sci U S A*. 1994;91(26):12594-12598.
165. Onder O, Humphrey PT, McOmber B, et al. OspC is potent plasminogen receptor on surface of *Borrelia burgdorferi*. *J Biol Chem*. 2012;287(20):16860-16868.
166. Sjobring U, Pohl G, Olsen A. Plasminogen, absorbed by *Escherichia coli* expressing curli or by *Salmonella enteritidis* expressing thin aggregative fimbriae, can be activated by simultaneously captured tissue-type plasminogen activator (t-PA). *Mol Microbiol*. 1994;14(3):443-452.
167. Kukkonen M, Saarela S, Lahteenmaki K, et al. Identification of two laminin-binding fimbriae, the type 1 fimbria of *Salmonella enterica* serovar typhimurium and the G fimbria of *Escherichia coli*, as plasminogen receptors. *Infect Immun*. 1998;66(10):4965-4970.
168. Ralph AP, Carapetis JR. Group A streptococcal diseases and their global burden. *Curr Top Microbiol Immunol*. 2013;368:1-27.
169. Frick IM, Shannon O, Neumann A, Karlsson C, Wikstrom M, Bjorck L. Streptococcal inhibitor of complement (SIC) modulates fibrinolysis and enhances bacterial survival within fibrin clots. *J Biol Chem*. 2018;293(35):13578-13591.
170. Lebeau C, Vandenesch F, Greenland T, Novick RP, Etienne J. Coagulase expression in *Staphylococcus aureus* is positively and negatively modulated by an agr-dependent mechanism. *J Bacteriol*. 1994;176(17):5534-5536.
171. Bokarewa MI, Jin T, Tarkowski A. *Staphylococcus aureus*: Staphylokinase. *Int J Biochem Cell Biol*. 2006;38(4):504-509.
172. Negron O, Flick MJ. Does fibrinogen serve the host or the microbe in *Staphylococcus* infection? *Curr Opin Hematol*. 2019;26(5):343-348.
173. Ko YP, Flick MJ. Fibrinogen Is at the Interface of Host Defense and Pathogen Virulence in *Staphylococcus aureus* Infection. *Semin Thromb Hemost*. 2016;42(4):408-421.
174. Liesenborghs L, Verhamme P, Vanassche T. *Staphylococcus aureus*, master manipulator of the human hemostatic system. *J Thromb Haemost*. 2018;16(3):441-454.
175. Wann, E.R., S. Gurusiddappa, and M. Hook, The fibronectin-binding MSCRAMM FnbpA of *Staphylococcus aureus* is a bifunctional protein that also binds to fibrinogen. *J Biol Chem*. 275(18): p. 13863-71 (2000).
176. Geoghegan, J.A., I.R. Monk, J.P. O'Gara, and T.J. Foster, Subdomains N2N3 of fibronectin binding protein A mediate *Staphylococcus aureus* biofilm formation and adherence to fibrinogen using distinct mechanisms. *J Bacteriol*. 195(11): p. 2675-83 (2013).
177. Piroth, L., et al., The fibrinogen- and fibronectin-binding domains of *Staphylococcus aureus* fibronectin-binding protein A synergistically promote endothelial invasion and experimental endocarditis. *Infect Immun*. 76(8): p. 3824-31 (2008).
178. Hawiger, J., et al., Identification of a region of human fibrinogen interacting with staphylococcal clumping factor. *Biochemistry*. 21(6): p. 1407-13 (1982).
179. Herman-Bausier, P., et al., *Staphylococcus aureus* clumping factor A is a force-sensitive molecular switch that activates bacterial adhesion. *Proc Natl Acad Sci U S A*. 115(21): p. 5564-5569 (2018).
180. McDevitt, D., P. Francois, P. Vaudaux, and T.J. Foster, Identification of the ligand-binding domain of the surface-located fibrinogen receptor (clumping factor) of *Staphylococcus aureus*. *Mol Microbiol*. 16(5): p. 895-907 (1995).
181. Higgins, J., et al., Clumping factor A of *Staphylococcus aureus* inhibits phagocytosis by human polymorphonuclear leucocytes. *FEMS Microbiol Lett*. 258(2): p. 290-6 (2006).
182. Malachowa, N., et al., Contribution of *Staphylococcus aureus* Coagulases and Clumping Factor A to Abscess Formation in a Rabbit Model of Skin and Soft Tissue Infection. *PLoS One*. 11(6): p. e0158293 (2016).

183. Loughman, A., et al., Roles for fibrinogen, immunoglobulin and complement in platelet activation promoted by *Staphylococcus aureus* clumping factor A. *Mol Microbiol.* 57(3): p. 804-18 (2005).
184. Ni Eidhin, D., et al., Clumping factor B (ClfB), a new surface-located fibrinogen-binding adhesin of *Staphylococcus aureus*. *Mol Microbiol.* 30(2): p. 245-57 (1998).
185. Miajlovic, H., et al., Both complement- and fibrinogen-dependent mechanisms contribute to platelet aggregation mediated by *Staphylococcus aureus* clumping factor B. *Infect Immun.* 75(7): p. 3335-43 (2007).
186. Walker, J.N., et al., Catheterization alters bladder ecology to potentiate *Staphylococcus aureus* infection of the urinary tract. *Proc Natl Acad Sci U S A.* 114(41): p. E8721-E8730 (2017).
187. Zhang, X., et al., Crystal structures of Bbp from *Staphylococcus aureus* reveal the ligand binding mechanism with Fibrinogen alpha. *Protein Cell.* 6(10): p. 757-66 (2015).
188. Vazquez, V., et al., Fibrinogen is a ligand for the *Staphylococcus aureus* microbial surface components recognizing adhesive matrix molecules (MSCRAMM) bone sialoprotein-binding protein (Bbp). *J Biol Chem.* 286(34): p. 29797-805 (2011).
189. Palma, M., et al., Extracellular fibrinogen-binding protein, Efb, from *Staphylococcus aureus* blocks platelet aggregation due to its binding to the alpha-chain. *J Biol Chem.* 276(34): p. 31691-7 (2001).
190. Ko, Y.P., et al., Binding of Efb from *Staphylococcus aureus* to fibrinogen blocks neutrophil adherence. *J Biol Chem.* 286(11): p. 9865-74 (2011).
191. Ko, Y.P., et al., Phagocytosis escape by a *Staphylococcus aureus* protein that connects complement and coagulation proteins at the bacterial surface. *PLoS Pathog.* 9(12): p. e1003816 (2013).
192. Cheng, A.G., et al., Genetic requirements for *Staphylococcus aureus* abscess formation and persistence in host tissues. *FASEB J.* 23(10): p. 3393-404 (2009).
193. Bertling, A., et al., Staphylococcal extracellular adherence protein induces platelet activation by stimulation of thiol isomerases. *Arterioscler Thromb Vasc Biol.* 32(8): p. 1979-90 (2012).
194. Chavakis, T., et al., *Staphylococcus aureus* extracellular adherence protein serves as anti-inflammatory factor by inhibiting the recruitment of host leukocytes. *Nat Med.* 8(7): p. 687-93 (2002).
195. Thomas, S., et al., The Complex Fibrinogen Interactions of the *Staphylococcus aureus* Coagulases. *Front Cell Infect Microbiol.* 9: p. 106 (2019).
196. Davis, S.L., et al., SdrG, a fibrinogen-binding bacterial adhesin of the microbial surface components recognizing adhesive matrix molecules subfamily from *Staphylococcus epidermidis*, targets the thrombin cleavage site in the Bbeta chain. *J Biol Chem.* 276(30): p. 27799-805 (2001).
197. Vanzieleghe, T., P. Herman-Bausier, Y.F. Dufrene, and J. Mahillon, *Staphylococcus epidermidis* Affinity for Fibrinogen-Coated Surfaces Correlates with the Abundance of the SdrG Adhesin on the Cell Surface. *Langmuir.* 31(16): p. 4713-21 (2015).
198. Brennan, M.P., et al., Elucidating the role of *Staphylococcus epidermidis* serine-aspartate repeat protein G in platelet activation. *J Thromb Haemost.* 7(8): p. 1364-72 (2009).
199. Whitnack, E. and E.H. Beachey, Inhibition of complement-mediated opsonization and phagocytosis of *Streptococcus pyogenes* by D fragments of fibrinogen and fibrin bound to cell surface M protein. *J Exp Med.* 162(6): p. 1983-97 (1985).
200. Ringdahl, U., et al., A role for the fibrinogen-binding regions of streptococcal M proteins in phagocytosis resistance. *Mol Microbiol.* 37(6): p. 1318-26 (2000).
201. Carlsson, F., C. Sandin, and G. Lindahl, Human fibrinogen bound to *Streptococcus pyogenes* M protein inhibits complement deposition via the classical pathway. *Mol Microbiol.* 56(1): p. 28-39 (2005).

202. Macheboeuf, P., et al., Streptococcal M1 protein constructs a pathological host fibrinogen network. *Nature*. 472(7341): p. 64-8 (2011).
203. Herwald, H., et al., M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. *Cell*. 116(3): p. 367-79 (2004).
204. Oehmcke, S., M. Morgelin, and H. Herwald, Activation of the human contact system on neutrophil extracellular traps. *J Innate Immun*. 1(3): p. 225-30 (2009).
205. Ginton, K., et al., Variable region in streptococcal M-proteins provides stable binding with host fibrinogen for plasminogen-mediated bacterial invasion. *J Biol Chem*. 292(16): p. 6775-6785 (2017).
206. Pietrocola, G., et al., Multiple interactions of FbsA, a surface protein from *Streptococcus agalactiae*, with fibrinogen: affinity, stoichiometry, and structural characterization. *Biochemistry*. 45(42): p. 12840-52 (2006).
207. Siau, C., et al., Group B streptococcus isolates from septic patients and healthy carriers differentially activate platelet signaling cascades. *Thromb Haemost*. 95(5): p. 836-49 (2006).
208. Pietrocola, G., et al., FbsA, a fibrinogen-binding protein from *Streptococcus agalactiae*, mediates platelet aggregation. *Blood*. 105(3): p. 1052-9 (2005).
209. Schubert, A., et al., The fibrinogen receptor FbsA promotes adherence of *Streptococcus agalactiae* to human epithelial cells. *Infect Immun*. 72(11): p. 6197-205 (2004).
210. Bierwagen, P., K. Szpotkowski, M. Jaskolski, and A. Urbanowicz, *Borrelia* outer surface protein C is capable of human fibrinogen binding. *FEBS J*. 286(12): p. 2415-2428 (2019).

FIGURE LEDGENDS

Figure 1. Fibrinogen structure and fibrin formation. **A**, Fibrinogen consists of three pairs of polypeptide chains, A α , B β and γ held together by 29 disulfide bonds. All three chains converge in a central E region, which contains the cleavage sites for thrombin (Fibrinopeptides A and B). The chains extend out of this central E region through a coil-coiled region to the D regions, where the beta and gamma chains reach their C-terminus. The alpha chain extends beyond this D region, as the alpha-C chain. **B**, Fibrinopeptide A is cleaved by thrombin from fibrinogen which aggregate via knob-hole interactions forming oligomers and then protofibrils. Fibrinopeptide B is then cleaved by thrombin, releasing the fibrinogen α C regions, which allows lateral aggregation to occur forming fibres. Factor XIIIa initially cross-links γ chains (red), followed by α chains (green).

Figure 2. Fibrin(ogen) in wound healing. Once bleeding is controlled the role of the blood clot extends far beyond the cessation of bleeding. Fibrinogen is converted to fibrin, which forms a cohesive network, and provides a provisional matrix for wound healing to begin. The structural composition of fibrin and the binding of fibrin to cells and proteins highly determine the wound healing process. Beyond behaving as a provisional matrix, fibrin actively recruits cells to trigger fibrin-mediated responses, such as cell adhesion, migration, proliferation, and tubule formation. Fibrin degradation products also play a role influencing cell recruitment, proliferation and migration. Removal of the fibrin network and its replacement with an organized network of collagen is essential for wound healing to proceed to conclusion.

Figure 3. Fibrin(ogen) in bacterial infection. Fibrinogen has a role in both host defence and bacterial virulence. Fibrin(ogen) can mediate host defence functions through several mechanisms including a barrier function whereby fibrin(ogen) acts as a first line of defence. Fibrinogen can also encapsulate microbes to prevent their growth and dissemination, and functions to directly or indirectly modulate host immune system activity to support recruitment and activation of immune cells. Microbes can also use fibrin(ogen) to promote pathogenicity and survival. These mechanisms include using fibrin as a shield to evade the immune response, breaking fibrin down to increase dissemination and expressing numerous virulence factors capable of engaging fibrin(ogen).

Table 1. Function of select fibrinogen-binding bacterial proteins

Bacteria	Protein family	Protein	Fibrinogen binding site	Function of fibrinogen binding
<i>S. aureus</i>	Microbial surface components recognising adhesive matrix molecules (MSCRAMM)	Fibronectin binding protein A (FnBPA)	γ-chain [175]	<ul style="list-style-type: none"> • Binding to immobilised fibrinogen [176], which facilitates early valve colonisation in experimental endocarditis [177]
		Clumping factor A, (ClfA)	C-terminal region of the γ-chain [178]	<ul style="list-style-type: none"> • Promotes bacterial attachment and colonisation of host tissues and biomedical devices under high physiological shear stress [179] • Promotes fibrinogen-dependent bacterial clumping in solution, and adherence of <i>S. aureus</i> to immobilised fibrin(ogen) [180] • Inhibition of phagocytosis [181] • Role in abscess formation [182] • Platelet activation [183]
		Clumping factor B, (ClfB)	Aα-chain [184]	<ul style="list-style-type: none"> • Activation of platelet aggregation [185] • Colonisation of the bladder and catheter, contributing to catheter associated urinary tract infections [186]
		Bone sialoprotein-binding protein, (BbP)	Aα-chain, residues 561-575 [187, 188]	<ul style="list-style-type: none"> • Binding to immobilised fibrinogen [189] • Inhibits thrombin-induced fibrinogen coagulation [189]
	Secretable expanded repertoire adhesive molecules (SERAM)	Extracellular fibrinogen binding protein, (Efb)	Aα chain of the D fragment [190, 191]	<ul style="list-style-type: none"> • Generation of a protective fibrinogen shield that suppresses platelet activation and protects from phagocytosis [191, 192] • Inhibits ADP-induced, fibrinogen-dependent platelet aggregation [189]
		Extracellular matrix binding protein, (Emp)	Not determined	<ul style="list-style-type: none"> • Role in abscess formation [192]
		Extracellular adherence protein, (Eap)	Not determined	<ul style="list-style-type: none"> • Eap induces fibrinogen binding to platelets and platelet aggregation [193] • Inhibits host leukocyte recruitment [194]
	Coagulases	Coagulase (Coa) and von Willebrand Factor binding protein (vWbp)	Bβ-chain [195]	<ul style="list-style-type: none"> • As well as binding to prothrombin for the generation of a protective fibrin(ogen) shield around <i>S. aureus</i>, these coagulases also bind soluble and immobilised fibrinogen [195]
<i>S. epidermidis</i>	MSCRAMM	Serine-aspartate repeat protein G (SdrG)	N-terminus of the Bβ chain [196]	<ul style="list-style-type: none"> • Inhibits thrombin-induced coagulation by binding to and covering the thrombin cleavage site in the fibrinogen Bβ chain [196] • Binding to fibrinogen-coated implanted medical devices [197] • Platelet activation [198]
<i>S. pyogenes</i> (Group A streptococcus)	M proteins	M proteins	D region [199]	<ul style="list-style-type: none"> • Resistance to phagocytosis [200, 201] • Formation of M protein-fibrinogen supramolecular networks [202], which activate neutrophils, resulting in release of inflammatory mediator heparin binding protein from neutrophils, causing vascular leakage [203] • Fibrinogen-M1 protein complex can trigger formation of neutrophil extracellular traps [204] • Binding to fibrinogen, allowing for subsequent binding of plasminogen to the M protein-bound fibrinogen, and activation by GAS-secreted streptokinase [205]
<i>S. agalactiae</i> (Group B streptococcus)		FbsA	D region [206]	<ul style="list-style-type: none"> • Binding to fibrinogen, and inducing fibrinogen-dependent platelet aggregation [207, 208] • Adherence of <i>S. agalactiae</i> to epithelial cells [209]
<i>B. burgdorferi</i>		Outer surface protein C (OspC)	E fragment [210]	<ul style="list-style-type: none"> • OspC slows clot formation [210]